

**1 PATIENT INFORMATION:**

Name: \_\_\_\_\_  
Address: \_\_\_\_\_  
City: \_\_\_\_\_ State: \_\_\_\_\_ Zip: \_\_\_\_\_  
Phone: \_\_\_\_\_ Alt. Phone: \_\_\_\_\_  
Email: \_\_\_\_\_  
DOB: \_\_\_\_\_ Gender:  M  F Caregiver: \_\_\_\_\_  
Height: \_\_\_\_\_ Weight: \_\_\_\_\_ Allergies: \_\_\_\_\_

**2 PRESCRIBER INFORMATION:**

Name: \_\_\_\_\_  
Address: \_\_\_\_\_  
City: \_\_\_\_\_ State: \_\_\_\_\_ Zip: \_\_\_\_\_  
Phone: \_\_\_\_\_ Fax: \_\_\_\_\_  
NPI: \_\_\_\_\_ DEA: \_\_\_\_\_  
Tax I.D.: \_\_\_\_\_  
Office Contact: \_\_\_\_\_ Phone: \_\_\_\_\_

**3 STATEMENT OF MEDICAL NECESSITY:** (Please Attach All Medical Documentation)

Date of Diagnosis: \_\_\_\_\_ Patient also taking Methotrexate?  Yes  No  
ICD-10: \_\_\_\_\_ Other: \_\_\_\_\_ Serious or active infection present?  Yes  No  
TB Test:  Positive  Negative Date: \_\_\_\_\_ Hep B and Hep C ruled out or  
LFT: ALT: \_\_\_\_\_ AST: \_\_\_\_\_ Date: \_\_\_\_\_ treatment started?  Yes  No  
Assessment:  Moderate  Mod to Severe  Severe Does patient have latex allergy?  Yes  No  
\_\_\_\_\_% BSA affected  
 Scalp  Face  Chest  Arms  Hands  Nails  
 Back  Groin  Buttocks  Legs  Other: \_\_\_\_\_  
 ISGA or  EASI

**If Prior Authorization is denied, recommended formulary alternatives will be provided to the prescriber based upon the patient's insurance coverage.**

**Prior Failed Treatments:** **Indicate Drug Name and Length of Treatment:**

5-ASA \_\_\_\_\_  
 Biologics \_\_\_\_\_  
 Corticosteroids \_\_\_\_\_  
 Immunosuppressants \_\_\_\_\_  
 Methotrexate \_\_\_\_\_  
 NSAIDS \_\_\_\_\_  
 Surgery \_\_\_\_\_  
 Topical/Oral Antibiotics \_\_\_\_\_  
 UVA  UVB \_\_\_\_\_  
 Others \_\_\_\_\_

**4 INJECTION TRAINING:**  Pharmacist to Provide Training  Patient Trained in MD Office  To be Administered by a Healthcare Provider  Manufacturer Nurse Support

**5 PICK UP OR DELIVERY:**  Delivery to Patient's Home  Delivery to Physician's Office  Pharmacy to Coordinate

**6 INSURANCE INFORMATION:** Please Include Front and Back Copies of Pharmacy and Medical Card

**PRESCRIPTION INFORMATION:** (Please be sure to choose both induction and maintenance dose where applicable)

Patient Name: \_\_\_\_\_ Patient's Date of Birth: \_\_\_\_\_

Medication	Dosage & Strength	Direction	QTY	Refills
<input type="checkbox"/> COSENTYX®	<b>Pediatric Plaque Psoriasis</b> <input type="checkbox"/> 75 mg/0.5 mL single-dose prefilled syringe <input type="checkbox"/> 150 mg/ mL single-dose Sensoready prefilled syringe <input type="checkbox"/> 150 mg/ mL single-dose Sensoready prefilled pen <input type="checkbox"/> For Healthcare Professional Use Only: 150 mg lyophilized powder in a single-dose vial for reconstitution	<b>Induction Dose:</b> <input type="checkbox"/> Pediatric patients 6 years and older <50kg: Inject 75 mg SC at weeks 0, 1, 2, 3, and 4 <input type="checkbox"/> Pediatric patients 6 years and older ≥ 50kg: Inject 150 mg SC at weeks 0, 1, 2, 3, and 4 <b>Maintenance Dose:</b> <input type="checkbox"/> Pediatric patients 6 years and older <50kg: Inject 75 mg SC every 4 weeks thereafter <input type="checkbox"/> Pediatric patients 6 years and older ≥50kg: Inject 150 mg SC at 4 weeks thereafter		
<input type="checkbox"/> DUPIXENT®	<b>Pediatric Atopic Dermatitis</b> <input type="checkbox"/> 300mg/2ml Prefilled Syringe <input type="checkbox"/> 200mg/1.14ml Prefilled Syringe <input type="checkbox"/> 300mg/2ml Prefilled Pen (only for 12 years and older)	<b>Induction Dose:</b> <input type="checkbox"/> ≥60kg: Inject 600mg SC (two 300mg injections) <input type="checkbox"/> 30 to <60kg: Inject 400mg SC (two 200mg injections) <input type="checkbox"/> 15 to <30kg: Inject 600mg SC (two 300mg injections) <b>Maintenance Dose:</b> <input type="checkbox"/> ≥60kg: Inject 300mg SC every other week <input type="checkbox"/> 30 to <60kg: Inject 200mg SC every other week <input type="checkbox"/> 15 to <30kg: Inject 300mg SC every 4 weeks	2	0
<input type="checkbox"/> HUMIRA®	<b>Hidradenitis Suppurativa</b> <input type="checkbox"/> Adolescent Hidradenitis Suppurativa 80mg/0.8ml and 40mg/0.4ml Starter pack <input type="checkbox"/> Adolescent Hidradenitis Suppurativa 40mg/0.4ml Starter Package <input type="checkbox"/> Hidradenitis Suppurativa: 80mg/0.8ml Starter pack <input type="checkbox"/> Hidradenitis Suppurativa: 40mg/0.4ml Starter pack <input type="checkbox"/> 40mg/0.4ml Pen <input type="checkbox"/> 80mg/0.8ml Pen <input type="checkbox"/> 40mg/0.4ml Prefilled Syringe <input type="checkbox"/> 80mg/0.8ml Prefilled Syringe	<b>Induction Dose:</b> <input type="checkbox"/> Adolescents 12 years and older 30kg to <60kg: Inject 80mg SC on day 1, then 40mg SC on day 8 and every other week thereafter <input type="checkbox"/> Adolescents 12 years and older ≥60kg: Inject two 80mg pens SC on day 1, then one 80mg pen SC on day 15 <input type="checkbox"/> Adolescents 12 years and older ≥60kg: Inject one 80mg pen SC on day 1, then 80mg pen SC on day 2, then one 80mg pen SC on day 15 <b>Maintenance Dose:</b> <input type="checkbox"/> Adolescents 12 years and older 30kg to <60kg: Inject 40mg every other week <input type="checkbox"/> Adolescents 12 years and older ≥60kg: Inject 40mg on day 29 then Inject 40mg every week <input type="checkbox"/> Adolescents 12 years and older ≥60kg: Inject 80mg on day 29 then Inject 80mg every other week	3 4 3 6	0 0 0 0
<input type="checkbox"/>				

**PRESCRIBER SIGNATURE:** I authorize pharmacy to act as my designee for initiating and coordinating insurance prior authorizations, nursing services and patient assistance programs.

Signature: \_\_\_\_\_ Date: \_\_\_\_\_ Signature: \_\_\_\_\_ Date: \_\_\_\_\_

**Substitution Permitted**

**Dispense As Written**

Prior authorization approval and insurance benefits will be determined by the payor based upon the patient's eligibility, medical necessity, and the terms of the patient's coverage, among other things. Participation in this program is not a guarantee of prior authorization or of payment.

**Confidentiality Notice:** This fax is intended to be delivered only to the named addressee and contains confidential information that may be protected health information under federal and state laws. If you are not the named addressee, you should not disseminate, distribute or copy this fax. Please inform the sender immediately if you have received this document in error and then destroy this document immediately.

**1 PATIENT INFORMATION:**

Name: \_\_\_\_\_  
Address: \_\_\_\_\_  
City: \_\_\_\_\_ State: \_\_\_\_\_ Zip: \_\_\_\_\_  
Phone: \_\_\_\_\_ Alt. Phone: \_\_\_\_\_  
Email: \_\_\_\_\_  
DOB: \_\_\_\_\_ Gender:  M  F Caregiver: \_\_\_\_\_  
Height: \_\_\_\_\_ Weight: \_\_\_\_\_ Allergies: \_\_\_\_\_

**2 PRESCRIBER INFORMATION:**

Name: \_\_\_\_\_  
Address: \_\_\_\_\_  
City: \_\_\_\_\_ State: \_\_\_\_\_ Zip: \_\_\_\_\_  
Phone: \_\_\_\_\_ Fax: \_\_\_\_\_  
NPI: \_\_\_\_\_ DEA: \_\_\_\_\_  
Tax I.D.: \_\_\_\_\_  
Office Contact: \_\_\_\_\_ Phone: \_\_\_\_\_

**3 STATEMENT OF MEDICAL NECESSITY:** (Please Attach All Medical Documentation)

Date of Diagnosis: \_\_\_\_\_ Patient also taking Methotrexate?  Yes  No  
ICD-10: \_\_\_\_\_ Other: \_\_\_\_\_ Serious or active infection present?  Yes  No  
TB Test:  Positive  Negative Date: \_\_\_\_\_ Hep B and Hep C ruled out or  
LFT: ALT: \_\_\_\_\_ AST: \_\_\_\_\_ Date: \_\_\_\_\_ treatment started?  Yes  No  
Assessment:  Moderate  Mod to Severe  Severe Does patient have latex allergy?  Yes  No  
\_\_\_\_\_% BSA affected  
 Scalp  Face  Chest  Arms  Hands  Nails  
 Back  Groin  Buttocks  Legs  Other: \_\_\_\_\_  
 ISGA or  EASI

**If Prior Authorization is denied, recommended formulary alternatives will be provided to the prescriber based upon the patient's insurance coverage.**

**Prior Failed Treatments:** **Indicate Drug Name and Length of Treatment:**

5-ASA \_\_\_\_\_  
 Biologics \_\_\_\_\_  
 Corticosteroids \_\_\_\_\_  
 Immunosuppressants \_\_\_\_\_  
 Methotrexate \_\_\_\_\_  
 NSAIDS \_\_\_\_\_  
 Surgery \_\_\_\_\_  
 Topical/Oral Antibiotics \_\_\_\_\_  
 UVA  UVB \_\_\_\_\_  
 Others \_\_\_\_\_

**4 INJECTION TRAINING:**  Pharmacist to Provide Training  Patient Trained in MD Office  To be Administered by a Healthcare Provider  Manufacturer Nurse Support

**5 PICK UP OR DELIVERY:**  Delivery to Patient's Home  Delivery to Physician's Office  Pharmacy to Coordinate

**6 INSURANCE INFORMATION:** Please Include Front and Back Copies of Pharmacy and Medical Card

**PRESCRIPTION INFORMATION:** (Please be sure to choose both induction and maintenance dose where applicable)

Patient Name: \_\_\_\_\_ Patient's Date of Birth: \_\_\_\_\_

Medication	Dosage & Strength	Direction	QTY	Refills
<input type="checkbox"/> HUMIRA®	<b>Juvenile Idiopathic Arthritis + Pediatric Uveitis</b> <input type="checkbox"/> 10mg/0.1ml Prefilled Syringe <input type="checkbox"/> 20mg/0.2ml Prefilled Syringe <input type="checkbox"/> 40mg/0.4ml Pen <input type="checkbox"/> 80mg/0.8ml Pen <input type="checkbox"/> 40mg/0.4ml Prefilled Syringe <input type="checkbox"/> 80mg/0.8ml Prefilled Syringe	<input type="checkbox"/> Pediatrics patients 2 years and older 10kg to <15kg: Inject 10mg SC every other week <input type="checkbox"/> Pediatrics patients 2 years and older 15kg to <30kg: Inject 20mg SC every other week <input type="checkbox"/> Pediatrics patients 2 years and older ≥30kg: Inject 40mg SC every other week	2	
<input type="checkbox"/> HUMIRA®	<b>Pediatric Crohn's Disease</b> <input type="checkbox"/> Pediatric Crohn's Starter Pack: 80mg/0.8ml, 40mg/0.4ml <input type="checkbox"/> Pediatric Crohn's Starter Pack: 80mg/0.8ml <input type="checkbox"/> 20mg/0.2ml Prefilled Syringe <input type="checkbox"/> 40mg/0.4ml Pen <input type="checkbox"/> 80mg/0.8ml Pen <input type="checkbox"/> 40mg/0.4ml Prefilled Syringe <input type="checkbox"/> 80mg/0.8ml Prefilled Syringe	<input type="checkbox"/> Induction Dose: <input type="checkbox"/> Pediatrics patients 6 years and older 17kg to <40kg: Inject one 80mg pen SC on day 1, then one 40mg pen SC on day 15 <input type="checkbox"/> Pediatrics patients 6 years and older ≥40kg: Inject two 80mg pens SC on day 1, then one 80mg pen SC on day 15 <input type="checkbox"/> Pediatrics patients 6 years and older ≥40kg: Inject one 80mg pen SC on day 1, then 80mg pen SC on day 2, then one 80mg pen SC on day 15 <input type="checkbox"/> Maintenance Dose: <input type="checkbox"/> Pediatrics patients 6 years and older 17kg to <40kg: Inject 20mg SC every other week <input type="checkbox"/> Pediatrics patients 6 years and older ≥40kg: Inject 40mg SC every other week	2 3 2	0 0
<input type="checkbox"/> HUMIRA®	<b>Pediatric Ulcerative Colitis</b> <input type="checkbox"/> Pediatric Ulcerative Colitis' Starter Pack: 80mg/0.8ml Pen <input type="checkbox"/> 20mg/0.2ml Prefilled Syringe <input type="checkbox"/> 40mg/0.4ml Pen <input type="checkbox"/> 80mg/0.8ml Pen <input type="checkbox"/> 40mg/0.4ml Prefilled Syringe <input type="checkbox"/> 80mg/0.8ml Prefilled Syringe	<input type="checkbox"/> Induction Dose: <input type="checkbox"/> Pediatric patients 5 years and older 20kg to 40kg: Inject 80mg SC at week 0 (day 1), then 40mg SC at week 1 (day 8), then 40mg SC at week 2 (day 15) <input type="checkbox"/> Pediatric patients 5 years and older > 40kg: Inject 160mg SC at week 0 (day 1), then 80mg SC at week 1 (day 8), then 40mg SC at week 2 (day 15) <input type="checkbox"/> Maintenance Dose: <input type="checkbox"/> Pediatric patients 5 years and older 20kg to 40kg: Inject 40mg SC every other week at week 4 (day 29) thereafter <input type="checkbox"/> Pediatric patients 5 years and older 20kg to 40kg: Inject 20mg SC every week at week 4 (day 29) thereafter <input type="checkbox"/> Pediatric patients 5 years and older > 40kg: Inject 80mg SC every other week at week 4 (day 29) thereafter <input type="checkbox"/> Pediatric patients 5 years and older > 40kg: Inject 40mg SC every week at week 4 (day 29) thereafter		
<input type="checkbox"/>				

*All strengths and dosages listed are Humira® Citrate Free*

**PRESCRIBER SIGNATURE:** I authorize pharmacy to act as my designee for initiating and coordinating insurance prior authorizations, nursing services and patient assistance programs.

Signature: \_\_\_\_\_ Date: \_\_\_\_\_ Signature: \_\_\_\_\_ Date: \_\_\_\_\_

**Substitution Permitted**

**Dispense As Written**

Prior authorization approval and insurance benefits will be determined by the payor based upon the patient's eligibility, medical necessity, and the terms of the patient's coverage, among other things. Participation in this program is not a guarantee of prior authorization or of payment.

**Confidentiality Notice:** This fax is intended to be delivered only to the named addressee and contains confidential information that may be protected health information under federal and state laws. If you are not the named addressee, you should not disseminate, distribute or copy this fax. Please inform the sender immediately if you have received this document in error and then destroy this document immediately.

**1 PATIENT INFORMATION:**

Name: \_\_\_\_\_  
Address: \_\_\_\_\_  
City: \_\_\_\_\_ State: \_\_\_\_\_ Zip: \_\_\_\_\_  
Phone: \_\_\_\_\_ Alt. Phone: \_\_\_\_\_  
Email: \_\_\_\_\_  
DOB: \_\_\_\_\_ Gender:  M  F Caregiver: \_\_\_\_\_  
Height: \_\_\_\_\_ Weight: \_\_\_\_\_ Allergies: \_\_\_\_\_

**2 PRESCRIBER INFORMATION:**

Name: \_\_\_\_\_  
Address: \_\_\_\_\_  
City: \_\_\_\_\_ State: \_\_\_\_\_ Zip: \_\_\_\_\_  
Phone: \_\_\_\_\_ Fax: \_\_\_\_\_  
NPI: \_\_\_\_\_ DEA: \_\_\_\_\_  
Tax I.D.: \_\_\_\_\_  
Office Contact: \_\_\_\_\_ Phone: \_\_\_\_\_

**3 STATEMENT OF MEDICAL NECESSITY:** (Please Attach All Medical Documentation)

Date of Diagnosis: \_\_\_\_\_ Patient also taking Methotrexate?  Yes  No  
ICD-10: \_\_\_\_\_ Other: \_\_\_\_\_ Serious or active infection present?  Yes  No  
TB Test:  Positive  Negative Date: \_\_\_\_\_ Hep B and Hep C ruled out or  
LFT: ALT: \_\_\_\_\_ AST: \_\_\_\_\_ Date: \_\_\_\_\_ treatment started?  Yes  No  
Assessment:  Moderate  Mod to Severe  Severe Does patient have latex allergy?  Yes  No  
\_\_\_\_\_% BSA affected  
 Scalp  Face  Chest  Arms  Hands  Nails  
 Back  Groin  Buttocks  Legs  Other: \_\_\_\_\_  
 ISGA or  EASI

**If Prior Authorization is denied, recommended formulary alternatives will be provided to the prescriber based upon the patient's insurance coverage.**

**Prior Failed Treatments:** **Indicate Drug Name and Length of Treatment:**

5-ASA \_\_\_\_\_  
 Biologics \_\_\_\_\_  
 Corticosteroids \_\_\_\_\_  
 Immunosuppressants \_\_\_\_\_  
 Methotrexate \_\_\_\_\_  
 NSAIDS \_\_\_\_\_  
 Surgery \_\_\_\_\_  
 Topical/Oral Antibiotics \_\_\_\_\_  
 UVA  UVB \_\_\_\_\_  
 Others \_\_\_\_\_

**4 INJECTION TRAINING:**  Pharmacist to Provide Training  Patient Trained in MD Office  To be Administered by a Healthcare Provider  Manufacturer Nurse Support

**5 PICK UP OR DELIVERY:**  Delivery to Patient's Home  Delivery to Physician's Office  Pharmacy to Coordinate

**6 INSURANCE INFORMATION:** Please Include Front and Back Copies of Pharmacy and Medical Card

**PRESCRIPTION INFORMATION:** (Please be sure to choose both induction and maintenance dose where applicable)

Patient Name: \_\_\_\_\_ Patient's Date of Birth: \_\_\_\_\_

Medication	Dosage & Strength	Direction	QTY	Refills
<input type="checkbox"/> <b>STELARA®</b>	<b>Pediatric Plaque Psoriasis</b> <input type="checkbox"/> 45mg/0.5ml Prefilled Syringe <input type="checkbox"/> 45mg/0.5ml Single-Dose Vial <input type="checkbox"/> 90mg/ml Prefilled Syringe	<input type="checkbox"/> <b>Induction Dose:</b> <input type="checkbox"/> Pediatric patients 6 years and older <60kg: Inject 0.75mg/kg SC at Week 0 <input type="checkbox"/> Pediatric patients 6 years and older 60 – 100kg: Inject 45mg SC at Week 0 <input type="checkbox"/> Pediatric patients 6 years and older >100kg: Inject 90mg SC at Week 0  <input type="checkbox"/> <b>Maintenance Dose:</b> <input type="checkbox"/> Pediatric patients 6 years and older <60kg: Inject 0.75mg/kg SC at Week 4, then every 12 weeks thereafter <input type="checkbox"/> Pediatric patients 6 years and older 60 – 100kg: Inject 45mg SC at Week 4, then every 12 weeks thereafter <input type="checkbox"/> Pediatric patients 6 years and older >100kg: Inject 90mg SC at Week 4, then every 12 weeks thereafter	1 1 0	0 0 0
<input type="checkbox"/> <b>TALTZ®</b>	<b>Pediatric Plaque Psoriasis</b> <input type="checkbox"/> 80mg/ml Single-Dose Prefilled Autoinjector <input type="checkbox"/> 80mg/ml Single-Dose Prefilled Syringe	<input type="checkbox"/> <b>Induction Dose:</b> <input type="checkbox"/> Pediatric patients 6 years and older <60kg: Inject 160mg SC (two 80mg injections) at week 0 <input type="checkbox"/> Pediatric patients 6 years and older 25 to 50kg: Inject 80 mg SC at week 0 <input type="checkbox"/> Pediatric patients 6 years and older <25kg: Inject 40mg SC at week 0  <input type="checkbox"/> <b>Maintenance Dose:</b> <input type="checkbox"/> Pediatric patients 6 years and older >50kg: Inject 80mg SC at week 4 and every 4 weeks thereafter <input type="checkbox"/> Pediatric patients 6 years and older 25 to 50kg: Inject 40 mg SC at week 4 and every 4 weeks thereafter <input type="checkbox"/> Pediatric patients 6 years and older <25kg: Inject 20 mg at week 4 and every 4 weeks thereafter  <i>20 mg and 40 mg doses for patients weighing ≤50 kg (110 lb) must be prepared and administered by a qualified healthcare professional.</i>	2 1	0
<input type="checkbox"/> <b>XELJANZ®</b>	<b>Polyarticular Course Juvenile Idiopathic Arthritis (pcJIA)</b> <input type="checkbox"/> 1mg/mL oral solution <input type="checkbox"/> 5mg tablets	<input type="checkbox"/> <b>Weight-Based Dosing</b> <input type="checkbox"/> Pediatric patients 2 years and older 10kg to < 20kg: Take 3.2 mg (3.2 mL oral solution) twice daily <input type="checkbox"/> Pediatric patients 2 years and older 20kg to < 40kg: Take 4 mg (4 mL oral solution) twice daily <input type="checkbox"/> Pediatric patients 2 years and older ≥ 40kg: Take 5 mg (one 5 mg oral tablet or 5 mL oral solution) twice daily  <input type="checkbox"/> Take 5 mg by mouth twice daily	60	
<input type="checkbox"/>				

**PRESCRIBER SIGNATURE:** I authorize pharmacy to act as my designee for initiating and coordinating insurance prior authorizations, nursing services and patient assistance programs.

Signature: \_\_\_\_\_ Date: \_\_\_\_\_ Signature: \_\_\_\_\_ Date: \_\_\_\_\_

**Substitution Permitted**

**Dispense As Written**

Prior authorization approval and insurance benefits will be determined by the payor based upon the patient's eligibility, medical necessity, and the terms of the patient's coverage, among other things. Participation in this program is not a guarantee of prior authorization or of payment.

**Confidentiality Notice:** This fax is intended to be delivered only to the named addressee and contains confidential information that may be protected health information under federal and state laws. If you are not the named addressee, you should not disseminate, distribute or copy this fax. Please inform the sender immediately if you have received this document in error and then destroy this document immediately.